SG11201805784PA - Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases - Google Patents
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseasesInfo
- Publication number
- SG11201805784PA SG11201805784PA SG11201805784PA SG11201805784PA SG11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- protein
- english
- pct
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/002,144 US20170204154A1 (en) | 2016-01-20 | 2016-01-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PCT/US2017/014090 WO2017127514A1 (en) | 2016-01-20 | 2017-01-19 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805784PA true SG11201805784PA (en) | 2018-08-30 |
Family
ID=59314394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805784PA SG11201805784PA (en) | 2016-01-20 | 2017-01-19 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US20170204154A1 (enExample) |
| EP (1) | EP3405482A4 (enExample) |
| JP (2) | JP6983787B2 (enExample) |
| KR (1) | KR20180100237A (enExample) |
| CN (1) | CN108602871A (enExample) |
| AU (2) | AU2017210187B2 (enExample) |
| BR (1) | BR112018014671A2 (enExample) |
| CA (1) | CA3010621A1 (enExample) |
| CL (1) | CL2018001951A1 (enExample) |
| CO (1) | CO2018008558A2 (enExample) |
| EA (1) | EA201891656A1 (enExample) |
| EC (1) | ECSP18062614A (enExample) |
| MX (1) | MX2018008840A (enExample) |
| SG (1) | SG11201805784PA (enExample) |
| WO (1) | WO2017127514A1 (enExample) |
| ZA (1) | ZA201804458B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EA201991142A1 (ru) | 2016-11-08 | 2019-10-31 | Варианты il-2 для лечения аутоиммунных заболеваний | |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3115461A1 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| SG11202008733YA (en) | 2018-03-13 | 2020-10-29 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| CN120590539A (zh) | 2018-03-28 | 2025-09-05 | 百时美施贵宝公司 | 白介素-2/白介素-2受体α融合蛋白以及使用方法 |
| JP2021530243A (ja) | 2018-07-25 | 2021-11-11 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規ｉｌ−２１プロドラッグおよびそれを使用する方法 |
| KR20210055070A (ko) | 2018-08-06 | 2021-05-14 | 메디카인 인코포레이티드 | Il-2 수용체 결합 화합물 |
| EP3856764A4 (en) * | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | MASKED CYTOKINE POLYPEPTIDES |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| MX2022001061A (es) | 2019-07-26 | 2022-02-14 | Visterra Inc | Agentes de interleuquina-2 y usos de los mismos. |
| CA3150978A1 (en) * | 2019-08-15 | 2021-02-18 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (il-2) polypeptides, conjugates and uses thereof |
| US20230057622A1 (en) * | 2019-09-16 | 2023-02-23 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant Human Neuregulin Derivatives and Use Thereof |
| WO2021092075A1 (en) | 2019-11-05 | 2021-05-14 | Medikine Inc. | IL-2RβγC BINDING COMPOUNDS |
| IL292803A (en) | 2019-11-05 | 2022-07-01 | Medikine Inc | Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof |
| US20210188934A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| IL295303A (en) | 2020-02-03 | 2022-10-01 | Medikine Inc | 7-il alpha receptor binding compounds and preparations containing them |
| MX2022009390A (es) | 2020-02-03 | 2022-11-16 | Medikine Inc | Compuestos de unión a il-7r¿¿c. |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| EP4149554A4 (en) | 2020-05-13 | 2024-05-29 | Bonum Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| TWI815194B (zh) * | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4236962A1 (en) | 2020-10-29 | 2023-09-06 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| CA3196844A1 (en) | 2020-11-25 | 2022-06-02 | Raphael Rozenfeld | Tumor-specific cleavable linkers |
| AU2021391924A1 (en) | 2020-12-04 | 2023-06-22 | The General Hospital Corporation | Methods of using interleukin-2 agents |
| CN113789346A (zh) * | 2021-08-25 | 2021-12-14 | 北京伟德杰生物科技有限公司 | 长效化重组人白细胞介素2融合蛋白及其制备方法和应用 |
| EP4475875A1 (en) * | 2022-02-11 | 2024-12-18 | Visterra, Inc. | Interleukin-2 muteins for the treatment of autoimmune diseases |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| CN115322260A (zh) * | 2022-06-13 | 2022-11-11 | 杭州高田生物医药有限公司 | 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用 |
| WO2024054868A1 (en) * | 2022-09-07 | 2024-03-14 | Xencor, Inc. | An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis |
| CN121002050A (zh) * | 2023-02-21 | 2025-11-21 | 艾诺康医药公司 | 编码经修饰的白细胞介素2（il2）多肽的多核苷酸以及其制备和使用方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| WO1990000565A1 (en) | 1988-07-05 | 1990-01-25 | Amgen Inc. | Interleukin ii analogs |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| WO1995008340A1 (en) | 1993-09-21 | 1995-03-30 | Amgen Inc. | Method for treating psoriasis |
| CZ20003099A3 (cs) | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| FI104522B (fi) | 1998-04-28 | 2000-02-15 | Abb Control Oy | Kytkinvarokerunko |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| CN1317301C (zh) | 2000-09-14 | 2007-05-23 | 贝斯以色列护理医疗中心有限公司 | Il－2－和il－15－介导的t细胞应答的调节 |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| JP4444652B2 (ja) | 2001-07-11 | 2010-03-31 | マキシゲン・ホールディングズ・リミテッド | Ｇ−ｃｓｆ結合体 |
| US7314712B2 (en) | 2001-07-27 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| DK1454138T3 (da) | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| WO2004060867A2 (en) | 2003-01-02 | 2004-07-22 | Timothy Kirk Gallaher | Secreted protein factor and cell membrane-bound splice variant |
| NZ543292A (en) | 2003-06-12 | 2008-04-30 | Lilly Co Eli | GLP-1 analog fusion proteins |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| ES2356154T3 (es) | 2003-07-21 | 2011-04-05 | Transgene S.A. | Citoquinas multifuncionales. |
| US7267960B2 (en) | 2003-07-25 | 2007-09-11 | Amgen Inc. | Antagonists and agonists of LDCAM and methods of use |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CA2595959A1 (en) | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics, Inc. | Methods for treating renal cell carcinoma |
| ES2289663T3 (es) | 2005-02-07 | 2008-02-01 | Novartis Vaccines And Diagnostics, Inc. | Preparacion de aldesleucina para uso farmaceutico. |
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| FR2918770B1 (fr) | 2007-07-10 | 2009-09-11 | Essilor Int | Afficheur destine a etre integre a une paire de lunettes. |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| CA2749539C (en) * | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| KR20120046163A (ko) | 2009-06-15 | 2012-05-09 | 바이오카인 테라퓨틱스 리미티드 | 자가면역, 염증 및 암의 과정을 저해할 수 있는 신규한 케모카인 결합 폴리펩타이드류 |
| JP6066732B2 (ja) | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| KR20200070407A (ko) | 2010-11-12 | 2020-06-17 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN102174111B (zh) | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| ES2694564T3 (es) | 2011-02-10 | 2018-12-21 | Roche Glycart Ag | Polipéptidos de interleucina-2 mutantes |
| US9669071B2 (en) | 2011-03-11 | 2017-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating T lymphocytes with IL-2 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| EP3421495A3 (en) * | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CN103193887B (zh) | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| EA201992609A1 (ru) | 2014-02-06 | 2020-03-04 | Ф.Хоффманн-Ля Рош Аг | Слитые белки, содержащие интерлейкин-2, и их применения |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| KR20150133576A (ko) | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| CN113234138A (zh) | 2014-08-11 | 2021-08-10 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体 |
| US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN115073581A (zh) | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| EA201991142A1 (ru) | 2016-11-08 | 2019-10-31 | Варианты il-2 для лечения аутоиммунных заболеваний |
-
2016
- 2016-01-20 US US15/002,144 patent/US20170204154A1/en not_active Abandoned
-
2017
- 2017-01-19 BR BR112018014671A patent/BR112018014671A2/pt not_active Application Discontinuation
- 2017-01-19 KR KR1020187023925A patent/KR20180100237A/ko not_active Ceased
- 2017-01-19 EP EP17741904.1A patent/EP3405482A4/en not_active Withdrawn
- 2017-01-19 MX MX2018008840A patent/MX2018008840A/es unknown
- 2017-01-19 EA EA201891656A patent/EA201891656A1/ru unknown
- 2017-01-19 CA CA3010621A patent/CA3010621A1/en active Pending
- 2017-01-19 AU AU2017210187A patent/AU2017210187B2/en not_active Ceased
- 2017-01-19 WO PCT/US2017/014090 patent/WO2017127514A1/en not_active Ceased
- 2017-01-19 SG SG11201805784PA patent/SG11201805784PA/en unknown
- 2017-01-19 JP JP2018538769A patent/JP6983787B2/ja not_active Expired - Fee Related
- 2017-01-19 CN CN201780007419.1A patent/CN108602871A/zh active Pending
- 2017-09-06 US US15/696,811 patent/US10294287B2/en active Active
-
2018
- 2018-07-03 ZA ZA2018/04458A patent/ZA201804458B/en unknown
- 2018-07-19 CL CL2018001951A patent/CL2018001951A1/es unknown
- 2018-08-15 CO CONC2018/0008558A patent/CO2018008558A2/es unknown
- 2018-08-20 EC ECSENADI201862614A patent/ECSP18062614A/es unknown
-
2019
- 2019-02-05 US US16/267,583 patent/US10875901B2/en not_active Expired - Fee Related
- 2019-03-13 US US16/352,249 patent/US10766938B2/en not_active Expired - Fee Related
- 2019-03-13 US US16/352,003 patent/US10774126B2/en not_active Expired - Fee Related
- 2019-12-30 US US16/729,698 patent/US11535657B2/en active Active
-
2020
- 2020-11-06 US US17/091,190 patent/US20210070828A1/en not_active Abandoned
-
2021
- 2021-10-26 AU AU2021257949A patent/AU2021257949A1/en not_active Abandoned
- 2021-11-24 JP JP2021189835A patent/JP2022058337A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108602871A (zh) | 2018-09-28 |
| JP2022058337A (ja) | 2022-04-12 |
| KR20180100237A (ko) | 2018-09-07 |
| US10875901B2 (en) | 2020-12-29 |
| JP6983787B2 (ja) | 2021-12-17 |
| AU2017210187B2 (en) | 2021-10-07 |
| MX2018008840A (es) | 2018-11-09 |
| ECSP18062614A (es) | 2018-10-31 |
| US20200115429A1 (en) | 2020-04-16 |
| US20180037624A1 (en) | 2018-02-08 |
| US20190153058A1 (en) | 2019-05-23 |
| JP2019507589A (ja) | 2019-03-22 |
| US10766938B2 (en) | 2020-09-08 |
| US11535657B2 (en) | 2022-12-27 |
| CA3010621A1 (en) | 2017-07-27 |
| US20170204154A1 (en) | 2017-07-20 |
| US20210070828A1 (en) | 2021-03-11 |
| US10294287B2 (en) | 2019-05-21 |
| AU2017210187A1 (en) | 2018-07-19 |
| CL2018001951A1 (es) | 2018-12-28 |
| AU2021257949A1 (en) | 2021-11-25 |
| ZA201804458B (en) | 2019-09-25 |
| WO2017127514A1 (en) | 2017-07-27 |
| US20190202882A1 (en) | 2019-07-04 |
| EA201891656A1 (ru) | 2018-12-28 |
| EP3405482A1 (en) | 2018-11-28 |
| EP3405482A4 (en) | 2019-06-26 |
| US10774126B2 (en) | 2020-09-15 |
| BR112018014671A2 (pt) | 2018-12-11 |
| CO2018008558A2 (es) | 2018-08-21 |
| US20190202881A1 (en) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
| SG11201808261RA (en) | Genetic variant-phenotype analysis system and methods of use | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201805253SA (en) | Compositions and methods related to multimodal therapeutic cell systems for cancer indications | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201805792PA (en) | Chimeric proteins and methods of regulating gene expression | |
| SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
| SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |